In last trading session, Apogee Therapeutics Inc (NASDAQ:APGE) saw 0.35 million shares changing hands with its beta currently measuring 2.17. Company’s recent per share price level of $41.36 trading at -$1.14 or -2.68% at ring of the bell on the day assigns it a market valuation of $2.42B. That closing price of APGE’s stock is at a discount of -74.78% from its 52-week high price of $72.29 and is indicating a premium of 20.74% from its 52-week low price of $32.78. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.53 million shares which gives us an average trading volume of 520.53K if we extend that period to 3-months.

Apogee Therapeutics Inc (NASDAQ:APGE) trade information

Upright in the red during last session for losing -2.68%, in the last five days APGE remained trading in the green while hitting it’s week-highest on Friday, 01/31/25 when the stock touched $41.36 price level, adding 6.02% to its value on the day. Apogee Therapeutics Inc’s shares saw a change of -8.70% in year-to-date performance and have moved 2.68% in past 5-day. Apogee Therapeutics Inc (NASDAQ:APGE) showed a performance of -7.35% in past 30-days. Number of shares sold short was 8.5 million shares which calculate 18.7 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 95 to the stock, which implies a rise of 56.46% to its current value. Analysts have been projecting 95 as a low price target for the stock while placing it at a high target of 95. It follows that stock’s current price would drop -129.69% in reaching the projected high whereas dropping to the targeted low would mean a loss of -129.69% for stock’s current value.

Apogee Therapeutics Inc (APGE) estimates and forecasts

Statistics highlight that Apogee Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -15.07% of value to its shares in past 6 months, showing an annual growth rate of 8.04% while that of industry is 16.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.

In 2025, company’s earnings growth rate is likely to be around 7.87% while estimates for its earnings growth in next 5 years are of -16.81%.

Apogee Therapeutics Inc (NASDAQ:APGE)’s Major holders

Insiders are in possession of 11.66% of company’s total shares while institution are holding 127.70 percent of that, with stock having share float percentage of 144.56%. Investors also watch the number of corporate investors in a company very closely, which is 127.70% institutions for Apogee Therapeutics Inc that are currently holding shares of the company.

On the other hand, Vanguard Specialized-Health Care Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 2.0 shares of worth $82.72 million or 4.44% of the total outstanding shares. The later fund manager was in possession of 1.43 shares on Oct 31, 2024 , making its stake of worth around $59.14 million in the company or a holder of 3.18% of company’s stock.